TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
$36.34-$1.18 (-3.14%) Today
Tal Zvi Zaks - DirectorTeva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 11 | 205,782 | $7.09M |
| Option exercise | 28 | 469,968 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
89 Form 4 filings on record, the earliest from Nov 21, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Amir Weiss - Officer | Open-market sale | Ordinary Shares | 6,945 | $37.61 | $261K | |
| Amir Weiss - Officer | Option exercise | Ordinary Shares | 2,500 | $19.61 | $49K | |
| Amir Weiss - Officer | Open-market sale | Ordinary Shares | 2,500 | $37.63 | $94K | |
| Amir Weiss - Officer | Option exercise | Stock Options (right to buy) | 2,500 | $19.16 | $48K | |
| Ronit Satchi-Fainaro - Director | Open-market sale | Ordinary Shares | 415 | $37.25 | $15K | |
| Evan Lippman - Officer | Open-market sale | Ordinary Shares | 18,600 | $36.57 | $680K | |
| Tal Zvi Zaks - Director | Open-market sale | Ordinary Shares | 17 | $34.87 | $593 | |
| Placid Jover - Officer | Option exercise | Ordinary Shares | 12,827 | - | - | |
| Placid Jover - Officer | Open-market sale | Ordinary Shares | 12,827 | $34.88 | $447K | |
| Placid Jover - Officer | Option exercise | Restricted Share Units | 12,827 | $0.00 | - | |
| Eric A. Hughes - Officer | Option exercise | Ordinary Shares | 52,744 | - | - | |
| Eric A. Hughes - Officer | Open-market sale | Ordinary Shares | 25,578 | $34.88 | $892K | |
| Eric A. Hughes - Officer | Option exercise | Restricted Share Units | 52,744 | $0.00 | - | |
| Matthew Shields - Officer | Open-market sale | Ordinary Shares | 9,989 | $32.19 | $322K | |
| Eliyahu Sharon Kalif - Officer | Open-market sale | Ordinary Shares | 106,563 | $34.10 | $3.63M | |
| Sol J. Barer | Option exercise | Ordinary Shares | 21,739 | - | - | |
| Sol J. Barer | Option exercise | Restricted Share Units | 21,739 | $0.00 | - | |
| Chen Lichtenstein | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Chen Lichtenstein | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
 Rosemary A. Crane | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Rosemary A. Crane | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
 Amir Elstein | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Amir Elstein | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Gerald M. Lieberman | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Gerald M. Lieberman | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Perry Nisen | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Perry Nisen | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Ronit Satchi-Fainaro | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Ronit Satchi-Fainaro | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Tal Zvi Zaks | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Tal Zvi Zaks | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Roberto Mignone | Option exercise | Ordinary Shares | 14,492 | - | - | |
| Roberto Mignone | Option exercise | Restricted Share Units | 14,492 | $0.00 | - | |
| Richard D. Francis - Officer | Option exercise | Ordinary Shares | 13,043 | - | - | |
| Richard D. Francis - Officer | Open-market sale | Ordinary Shares | 6,153 | $34.35 | $211K | |
| Richard D. Francis - Officer | Option exercise | Restricted Share Units | 13,043 | $0.00 | - | |
| Matthew Shields - Officer | Option exercise | Ordinary Shares | 16,195 | - | - | |
| Matthew Shields - Officer | Open-market sale | Ordinary Shares | 16,195 | $32.87 | $532K | |
| Matthew Shields - Officer | Option exercise | Restricted Share Units | 16,195 | $0.00 | - | |
| Tal Zvi Zaks | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Ronit Satchi-Fainaro | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Perry Nisen | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Gerald M. Lieberman | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Amir Elstein | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Rosemary A. Crane | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Chen Lichtenstein | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Sol J. Barer | Grant or award | Restricted Share Units | 10,863 | $0.00 | - | |
| Roberto Mignone | Grant or award | Restricted Share Units | 7,242 | $0.00 | - | |
| Evan Lippman - Officer | Option exercise | Ordinary Shares | 11,841 | - | - | |
| Evan Lippman - Officer | Open-market sale | Ordinary Shares | 5,746 | $35.58 | $204K | |
| Evan Lippman - Officer | Option exercise | Ordinary Shares | 74,008 | - | - | |
| Evan Lippman - Officer | Open-market sale | Ordinary Shares | 35,912 | $35.58 | $1.28M | |
| Evan Lippman - Officer | Option exercise | Restricted Share Units | 11,841 | $0.00 | - | |
| Evan Lippman - Officer | Option exercise | Restricted Share Units | 74,008 | $0.00 | - | |
| Eliyahu Sharon Kalif - Officer | Open-market sale | Ordinary Shares | 153,251 | $35.61 | $5.46M |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Lippman Evan | Officer, EVP BUSINESS DEVELOPMENT | 18,600 | $680K | View on EDGAR | |
| Jover Placid | Executive VP, Chief HR Officer | 12,827 | $447K | View on EDGAR | |
| Hughes Eric A | Executive VP Global R&D and Chief Med Officer | 25,578 | $892K | View on EDGAR |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) had 19 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for TEVA runs to 89 Form 4 filings, the earliest from 2024-11-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TEVA were filed in the last 90 days. 1 purchase is on record for this company.
11 insider sales of TEVA were filed in the last 90 days, totaling $7.09M.
This page tracks TEVA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TEVA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
